A New Era
HIV prevention has come a long way since the early days of the epidemic, and pre-exposure prophylaxis (PrEP) stands as one of the most powerful tools available today. Taken daily, PrEP can reduce the risk of contracting HIV through sexual activity by 99%, offering life-saving protection.
Yet, challenges with adherence and access have left some at risk. Gilead’s latest innovation, a long-acting injectable PrEP option that provides six months of protection with a single dose, addresses this gap in care to ensure widespread effectiveness.
Clinical trials show that this biannual injection reduces HIV transmission rates by 96%, offering an alternative to the daily pill regimen. For individuals facing barriers to consistent medication, this breakthrough brings hope.
“This innovation isn’t just a step forward; it’s a game-changer for public health,” says Dr. Bob Wallace, founder of Love The Golden Rule. “We’re witnessing a new chapter in the fight against HIV/AIDS, which allows for incredible availability for HIV treatment in developing nations and low-income communities.”
Gilead's New Six-Month Injectable PrEP
Gilead’s long-acting PrEP injection, known as lenacapavir, is the first HIV prevention method requiring only two doses a year. This medication works by inhibiting the HIV capsid protein, which is essential for the virus’s replication. Unlike daily pills, lenacapavir offers a discreet, low-maintenance solution, ideal for individuals with busy lifestyles or difficulty adhering to daily regimens.
The data surrounding lenacapavir is promising:
Efficacy: A Phase 3 study reported a 96% reduction in HIV transmission rates.
Adherence Benefits: Participants in clinical trials overwhelmingly preferred the biannual injection to the daily oral alternative.
Safety Profile: Side effects were generally mild and included injection site reactions, headache, and nausea. Serious adverse effects were rare, making it a safe option for most individuals.
The introduction of lenacapavir marks a turning point in public health. As Dr. Colleen Kelley, a researcher involved in the trials, notes: “Seeing nearly 100% efficacy with such a convenient regimen is incredible—it can truly reshape how we approach HIV prevention.”
For communities disproportionately affected by HIV—particularly people of color and LGBTQ+ individuals—this injectable option removes significant barriers, expanding access and improving outcomes. While clinical trials are still being completed, initial results seem extremely promising, and it has been provisionally approved by the FDA for use in treatment resistant cases.
If you or someone you know is interested in learning more about PrEP, including receiving Gilead’s new treatment, lenacapavir, once available, reach out to us here, or at the button below.
Love The Golden Rule's Legacy and World AIDS Day Impact
For Dr. Wallace, the battle against HIV/AIDS is deeply personal. Early in his career, he contributed to the development of medications now used in ten different combination therapies, transforming lives around the globe.
“In the 1980s, we were racing against time to save lives,” Dr. Wallace recalls. “To see that work now making such an impact is profoundly rewarding.”
We were proud to demonstrate this commitment to innovation and community support during our recent World AIDS Day events. Held across the week of December 1st, these gatherings raised awareness and funds while providing essential services to the community:
- $10,391 Raised: Through a combination of ticket sales, community donations, auction sales, we were able to raise a record amount. These funds will further our efforts of providing testing and treatment for HIV and HEP-C, regardless of a patient’s ability to pay.
- 100 Attendees: Community members came together to honor those affected by HIV/AIDS and celebrate progress in prevention.
- Free Testing: Over a dozen individuals received free Hepatitis C and HIV testing, ensuring access to crucial healthcare resources.
- Education and Outreach: Thanks to our partners, Gilead and ViiV, we were able to offer resources that further education and outreach efforts.
PrEP is for Everyone
PrEP isn’t just for individuals at high risk—it’s for anyone who wants to take control of their health. Gilead’s new six-month injectable option makes prevention more accessible than ever, addressing the challenges of daily pill adherence and broadening the reach of this life-saving tool.
At Love The Golden Rule, we are particularly passionate about this innovation because of its potential to help the high-risk members of our community, a group we have made it our mission to serve. The doubling of HIV rates among women of color in Tampa Bay, as highlighted in a recent ABC Action News feature on our clinic, underscores the urgent need for accessible and effective prevention tools.
“Women of color and LGBTQ+ individuals often face the greatest barriers to healthcare,” says Dr. Bob Wallace, founder of Love The Golden Rule. “Innovations like Gilead’s injectable PrEP open new doors for equitable access, empowering individuals to take control of their health and their future.”
As we reflect on the progress made this World AIDS Day, we remain steadfast in our mission to create a future without HIV. By focusing on outreach, education, and cutting-edge prevention methods, we’re working to ensure that no one in our community is left behind.